+

WO2002050263A3 - Procedes - Google Patents

Procedes Download PDF

Info

Publication number
WO2002050263A3
WO2002050263A3 PCT/GB2001/005722 GB0105722W WO0250263A3 WO 2002050263 A3 WO2002050263 A3 WO 2002050263A3 GB 0105722 W GB0105722 W GB 0105722W WO 0250263 A3 WO0250263 A3 WO 0250263A3
Authority
WO
WIPO (PCT)
Prior art keywords
bone
derived stem
marrow derived
tissue damage
stem cell
Prior art date
Application number
PCT/GB2001/005722
Other languages
English (en)
Other versions
WO2002050263A2 (fr
Inventor
Stuart Forbes
Malcolm Alison
Nick Wrigth
Mike Themis
Richard Poulsom
Howard Thomas
Original Assignee
Imp College Innovations Ltd
Stuart Forbes
Malcolm Alison
Nick Wrigth
Mike Themis
Richard Poulsom
Howard Thomas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imp College Innovations Ltd, Stuart Forbes, Malcolm Alison, Nick Wrigth, Mike Themis, Richard Poulsom, Howard Thomas filed Critical Imp College Innovations Ltd
Priority to AU2002216243A priority Critical patent/AU2002216243A1/en
Publication of WO2002050263A2 publication Critical patent/WO2002050263A2/fr
Publication of WO2002050263A3 publication Critical patent/WO2002050263A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une cellule souche de moelle osseuse comportant un acide nucléique recombiné qui peut exprimer, dans cette cellule souche de moelle osseuse ou dans une cellule dérivée de celle-ci, un produit thérapeutique. Cette cellule souche de moelle osseuse peut être utilisée dans le traitement de lésions tissulaires, de lésions du foie par exemple, ou dans la correction d'un défaut génétique. Des compositions, qui favorisent la mobilisation des cellules souches et leur maturation en un type désiré de cellules différenciées, peuvent être administrées au patient. La cellule souche de moelle osseuse peut comporter un acide nucléique recombiné pouvant exprimer un produit cytotoxique. Cela peut être utile dans l'élimination des cellules recombinées du patient, si ces cellules ne sont plus nécessaires.
PCT/GB2001/005722 2000-12-21 2001-12-21 Procedes WO2002050263A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002216243A AU2002216243A1 (en) 2000-12-21 2001-12-21 Methods_for treating tissue damage by bone-marrow derived stem cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0031390.8 2000-12-21
GBGB0031390.8A GB0031390D0 (en) 2000-12-21 2000-12-21 Methods

Publications (2)

Publication Number Publication Date
WO2002050263A2 WO2002050263A2 (fr) 2002-06-27
WO2002050263A3 true WO2002050263A3 (fr) 2003-02-06

Family

ID=9905694

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/005722 WO2002050263A2 (fr) 2000-12-21 2001-12-21 Procedes

Country Status (3)

Country Link
AU (1) AU2002216243A1 (fr)
GB (1) GB0031390D0 (fr)
WO (1) WO2002050263A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004090121A2 (fr) * 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd Cellules souches presentant une sensibilite accrue a un agent chimio-attractif, methodes de production et d'utilisation associees
WO2004091661A1 (fr) * 2003-04-15 2004-10-28 Chugai Seiyaku Kabushiki Kaisha Remede contre le diabete
WO2014055413A2 (fr) * 2012-10-02 2014-04-10 Bloodcenter Research Foundation Procédé permettant de fournir une thérapie cellulaire à l'aide de cellules tueuses naturelles modifiées ou de lymphocytes t

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0938904A1 (fr) * 1998-02-09 1999-09-01 Leuven Research & Development vzw Transduction des cellules mammifères pour utilisation dans la thérapie génique
WO1999061589A2 (fr) * 1998-05-28 1999-12-02 St. Jude Children's Research Hospital Dilatation des cellules souches hematopoietiques transduites par mdr-1 et leurs procedes d'utilisation
WO2000049141A2 (fr) * 1998-06-08 2000-08-24 Acgt Corporation Procede de production et d'administration d'une proteine in vivo

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0938904A1 (fr) * 1998-02-09 1999-09-01 Leuven Research & Development vzw Transduction des cellules mammifères pour utilisation dans la thérapie génique
WO1999061589A2 (fr) * 1998-05-28 1999-12-02 St. Jude Children's Research Hospital Dilatation des cellules souches hematopoietiques transduites par mdr-1 et leurs procedes d'utilisation
WO2000049141A2 (fr) * 1998-06-08 2000-08-24 Acgt Corporation Procede de production et d'administration d'une proteine in vivo

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
ABONOUR RAFAT ET AL: "Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells.", NATURE MEDICINE, vol. 6, no. 6, June 2000 (2000-06-01), pages 652 - 658, XP002195492, ISSN: 1078-8956 *
ALISON M R ET AL: "Hepatocytes from non-hepatic adult stem cells", NATURE, vol. 406, no. 6793, 20 July 2000 (2000-07-20), ENGLAND, pages 257, XP002195493 *
ALISON M R ET AL: "Plasticity of human haemopoietic stem cells: Differentiation to hepatocytes after liver and bone marrow transplantation.", JOURNAL OF PATHOLOGY, vol. 192, no. Supplement, September 2000 (2000-09-01), 181st Meeting of the Pathological Society of Great Britain and Ireland;Nottingham, UK; July 12-14, 2000, pages 2A, XP001068550, ISSN: 0022-3417 *
ALISON MALCOLM R ET AL: "Update on hepatic stem cells.", LIVER, vol. 21, no. 6, December 2001 (2001-12-01), pages 367 - 373, XP002195495, ISSN: 0106-9543 *
DING L ET AL: "Bone marrow stromal cells as a vehicle for gene transfer.", GENE THERAPY, vol. 6, no. 9, 1999, pages 1611 - 1616, XP001068619, ISSN: 0969-7128 *
GUPTA SANJEEV ET AL: "Liver repopulation with hepatocyte transplantation: new avenues for gene and cell therapy", THE JOURNAL OF GENE MEDICINE, vol. 1, no. 6, November 1999 (1999-11-01), pages 386 - 392, XP001068452 *
GUSSONI E ET AL: "DYSTROPHIN EXPRESSION IN THE MDX MOUSE RESTORED BY STEM CELL TRANSPLANTATION", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 401, 23 September 1999 (1999-09-23), pages 390 - 394, XP000867084, ISSN: 0028-0836 *
KRAUSE DIANE S ET AL: "Multi-organ, multilineage engraftment by a single bone marrow-derived stem cell after transplantation in mice.", BLOOD, vol. 96, no. 11 Part 1, 16 November 2000 (2000-11-16), 42nd Annual Meeting of the American Society of Hematology;San Francisco, California, USA; December 01-05, 2000, pages 494a, XP001068585, ISSN: 0006-4971 *
LAGASSE E ET AL: "PURIFIED HEMATOPOIETIC STEM CELLS CAN DIFFERENTIATE INTO HEPATOCYTES IN VIVO", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 6, no. 11, November 2000 (2000-11-01), pages 1229 - 1234, XP001037072, ISSN: 1078-8956 *
PETERSEN B E ET AL: "Bone marrow as a potential source of hepatic oval cells", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 284, no. 5417, 14 May 1999 (1999-05-14), pages 1168 - 1170, XP002147735, ISSN: 0036-8075 *
TERADA ET AL: "Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion", NATURE, 13 March 2002 (2002-03-13), ENGLAND, XP002195496, Retrieved from the Internet <URL:www.nature.com (DOI 10.1038/nature730)> [retrieved on 20020324] *
THEISE NEIL D ET AL: "Liver from bone marrow in humans.", HEPATOLOGY, vol. 32, no. 1, July 2000 (2000-07-01), pages 11 - 16, XP001057272, ISSN: 0270-9139 *
WANG XIN ET AL: "Therapeutic liver reconstitution by adult pancreatic cells and adult bone marrow derived hematopoietic stem cells.", HEPATOLOGY, vol. 32, no. 4 Pt. 2, October 2000 (2000-10-01), 51st Annual Meeting and Postgraduate Courses of the American Association for the Study of Liver Diseases;Dallas, Texas, USA; October 27-31, 2000, pages 296A, XP001068604, ISSN: 0270-9139 *
YING ET AL: "Changing potency by spontaneous fusion", NATURE, 13 March 2002 (2002-03-13), ENGLAND, XP002195497, Retrieved from the Internet <URL:www.nature.com (DOI 10.1038/nature729)> [retrieved on 20020324] *

Also Published As

Publication number Publication date
GB0031390D0 (en) 2001-02-07
AU2002216243A1 (en) 2002-07-01
WO2002050263A2 (fr) 2002-06-27

Similar Documents

Publication Publication Date Title
WO2005011569A3 (fr) Methodes comprenant l&#39;utilisation de cellules derivees du tissu adipeux pour le transfert de graisse autologue a des fins d&#39;augmentation
WO1999046366A8 (fr) Utilisations de cellules souches humaines mesenchymateuses non autologues
EP1460131A3 (fr) Préparation de facteurs de la coagulation sanguine recombinants en lignées cellulaires humaines
WO2003007873A3 (fr) Matrices a base de proteines de plasma et procedes de fabrication
WO2004047747A3 (fr) Compositions et procedes de dedifferentiation cellulaire et de regeneration de tissus
WO2004019884A3 (fr) Agents et procedes pour stimuler la formation osseuse
WO2000012072A3 (fr) Utilisation de derives d&#39;acide fumarique dans la medecine de transplantation
WO2004009767A3 (fr) Therapie cellulaire de regeneration
CN102056619A (zh) 产生和使用原胶原的方法
WO2006071778A3 (fr) Traitement de la maladie de parkinson et de troubles associes au moyen de cellules derivees postnatales
WO2007035356A3 (fr) Dispositifs et procedes de traitement du glaucome
CA2416492A1 (fr) Traitement de la glycogenose de type ii
WO2006127007A3 (fr) Procedes d&#39;utilisation de cellules derivees de tissus adipeux dans le traitement de maladies cardiovasculaires
WO2002045431A3 (fr) Herpèsvirus obtenu par génie génétique pour le traitement d&#39;affections cardio-vasculaires
WO1994006449A3 (fr) Regeneration du foie induite par des morphogenes
WO2001068828A3 (fr) Compositions et methodes destinees a l&#39;expression regulee d&#39;une proteine dans l&#39;intestin
WO2002004409A3 (fr) Agents neuroprotecteurs à base d&#39;analogues de tétrahydrobenzothiazole
EP2330111A3 (fr) Oligoribonucléotides et procédés d&#39;utilisation de ceux-ci dans le traitement d&#39;états fibreux et d&#39;autres maladies
WO2005047469A3 (fr) Proteine isogloboside 3 synthase porcine, adnc, organisation genomique, et region regulatrice
WO2002092013A3 (fr) Methodes de traitement des maladies du foie et des lesions du foie a l&#39;aide de l&#39;hormone de croissance et de la proteine foxm1b
WO2006116185A3 (fr) Procedes destines au traitement de myelomes multiples
WO2002022646A3 (fr) Procede de preparation de 21-hydroxy-6,19-oxydoprogesterone (21oh-6op)
WO2002050263A3 (fr) Procedes
WO2005054446A3 (fr) Utilisation d&#39;alginate polysulfaté dans des matrices cellulaires
WO2004010934A3 (fr) Methodes d&#39;utilisation de la neurotoxine dans le traitement de troubles urologiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载